Literature DB >> 3359923

Metformin in the digestive tract.

N Vidon1, S Chaussade, M Noel, C Franchisseur, B Huchet, J J Bernier.   

Abstract

After ingestion of metformin, a drug of the biguanide class, there are gastrointestinal effects in the form of nausea and vomiting, and about 30% of the drug is recovered in feces. The purpose of this work was to explain these two phenomena. Two sets of experiments were carried out. Study I evaluated the gastroduodenal (GD) absorption in six healthy volunteers by means of an intubation method, employing a twin-lumen tube introduced into the intestine and another into the stomach. Metformin 1 g was introduced into the stomach with a homogenized meal containing a non-absorbable marker, 14C-PEG 4000; another marker, PEG 4000, was perfused continuously into the duodenum at the ampulla of Vater. Samples of GD contents were collected every 15 min during 4 h. Metformin was poorly absorbed from the stomach, about 10% over a 4-h period. It did not modify the gastric emptying of a meal but induced a duodeno-gastric reflux in five out of six subjects. About 20% of the amount of drug emptied from the stomach were absorbed from the duodenum. The delivery process was the rate-limiting factor for metformin absorption from the duodenum. The AUC/24 h increased as the absorption rate from the duodenum increased. Study 2 investigated in six healthy volunteers, using another intestinal perfusion technique, the jejunal and ileal absorption of metformin. Metformin 400 mg in saline solution was perfused, over a 2-h period, below an inflated balloon, directly into either the jejunum or the ileum.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3359923     DOI: 10.1016/s0168-8227(88)80022-6

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  20 in total

Review 1.  Potential applications for biguanides in oncology.

Authors:  Michael Pollak
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

2.  Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial.

Authors:  Mette Marie H Christensen; Kurt Højlund; Ole Hother-Nielsen; Tore B Stage; Per Damkier; Henning Beck-Nielsen; Kim Brøsen
Journal:  Diabetologia       Date:  2015-08-14       Impact factor: 10.122

3.  Steady-state pharmacokinetics of a novel extended-release metformin formulation.

Authors:  Peter Timmins; Steve Donahue; Jeff Meeker; Punit Marathe
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Relative bioavailability of chlorothiazide from mucoadhesive compacts in pigs.

Authors:  Karunakar Neelam; Ravichandran Mahalingam; Raj Birudaraj; Tom Alfredson; Pratap Anne; Xiaoling Li; Bhaskara R Jasti
Journal:  AAPS PharmSciTech       Date:  2009-11-10       Impact factor: 3.246

5.  Intestinal permeability of metformin using single-pass intestinal perfusion in rats.

Authors:  Nai-Ning Song; Quan-Sheng Li; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

6.  Bilayer matrix tablets for prolonged actions of metformin hydrochloride and repaglinide.

Authors:  Wei He; Shijing Huang; Chunyan Zhou; Lin Cao; Jing Yao; Jianping Zhou; Guangji Wang; Lifang Yin
Journal:  AAPS PharmSciTech       Date:  2014-10-16       Impact factor: 3.246

Review 7.  Clinical pharmacokinetics of metformin.

Authors:  A J Scheen
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

8.  Effect of gastric bypass surgery on the absorption and bioavailability of metformin.

Authors:  Raj S Padwal; Raniah Q Gabr; Arya M Sharma; Lee-Ann Langkaas; Dan W Birch; Shahzeer Karmali; Dion R Brocks
Journal:  Diabetes Care       Date:  2011-04-08       Impact factor: 19.112

9.  Efficacy and Side Effect Profile of Different Formulations of Metformin: A Systematic Review and Meta-Analysis.

Authors:  Jane L Tarry-Adkins; Imogen D Grant; Susan E Ozanne; Rebecca M Reynolds; Catherine E Aiken
Journal:  Diabetes Ther       Date:  2021-06-02       Impact factor: 2.945

10.  Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: an observational trial in Asia.

Authors:  Chul-Hee Kim; Kyung-Ah Han; Han-Jin Oh; Kevin Eng-Kiat Tan; Radhakrishna Sothiratnam; Askandar Tjokroprawiro; Marcus Klein
Journal:  J Diabetes       Date:  2012-12       Impact factor: 4.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.